GC Biopharma
Key metrics
Earnings
| Revenue, Q3 2026 | ₩522.1bn |
|---|---|
| Revenue QoQ | +24.0% |
| Revenue YoY | -14.3% |
| Operating income, Q3 2026 | ₩49.2bn |
| Operating income QoQ | +2746.1% |
| Operating income YoY | +68.5% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩59.2bn |
|---|---|
| Supply contracts vs prior-year revenue | 3.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 4 |
|---|---|
| DART filings, previous 3 months | 12 |
Insider transactions
| Open-market buys, last 12 months (shares) | 750 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩89m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 750 shares |
| Insiders who bought, last 12 months | 2 |
Insider transactions (last 12 months)
Open-market buys: 750 shares (₩89m). Open-market sells: 0 shares (₩0). Net open-market buying: +750 shares. Insiders who bought: 2.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Choi Yeong-il (Non-registered officer) | Open-market buy | +500 shares | ₩117,800 | ₩59m | |
| Jun 15, 2026 | Jung Jae-uk (Registered director) | Open-market buy | +250 shares | ₩121,348 | ₩30m | |
| Jan 1, 2026 | Son Seok-u (Non-registered officer) | Other (New report) | +25 shares | — | — |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩2.0tn | ₩69.1bn |
| 2024 | ₩1.7tn | ₩32.1bn |
| 2023 | ₩1.6tn | ₩34.4bn |
Filing timeline
-
GC Biopharma signs ₩59.2bn influenza vaccine supply contract
GC Biopharma filed a supply contract for influenza vaccines with VaxThera Zona Franca S.A.S., with a contract amount of ₩59.2bn. The filing reports the contract as 3.0% of revenue, and the contract period runs from Oct 30, 2026 to Oct 30, 2036. The filing date is Nov 2, 2026.
-
GC Biopharma signs ₩142.1bn Brazil export supply contract
GC Biopharma filed a Brazil export supply contract with BLAU Farmaceutica S.A. worth ₩142.1bn, reported as 8.3% of revenue. The contract period runs from Jun 30, 2023 to Jun 29, 2028.